Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834171 · ClinicalTrials.gov registry record
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 50
- Enrollment target
NCT00834171: Completed study, sponsored by Allergan.
NCT00834171 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834171 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
Primary Outcome
Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.
Interventions
- DRUG Loteprednol etabonate ophthalmic suspension 0.5%
- DRUG Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-12 |
What the finished NCT00834171 record still lists
NCT00834171 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol etabonate ophthalmic suspension 0.5% is the first listed.
NCT00834171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00834171 about?
NCT00834171 is a clinical study titled "A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin". Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
What is the current status of trial NCT00834171?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2009-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00834171?
The interventions under investigation include: Loteprednol etabonate ophthalmic suspension 0.5% (DRUG), Loteprednol etabonate (0.5%) and tobramycin (0.3%). (DRUG).
Who is sponsoring clinical trial NCT00834171?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia